Balanitis News and Research RSS Feed - Balanitis News and Research

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes. [More]
EU approves Forxiga for treatment of type 2 diabetes

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes. [More]
Antifungal resistance of Candida genital isolates on the increase

Antifungal resistance of Candida genital isolates on the increase

Resistance to antifungal therapy of genital-infection causing Candida species may be an increasing problem, suggests research presented at the European Academy of Dermatology and Venereology annual congress in Prague, Czech Republic. [More]
Antifungal resistance of Candida genital isolates on the increase

Antifungal resistance of Candida genital isolates on the increase

Resistance to antifungal therapy of genital-infection causing Candida species may be an increasing problem, suggests research presented at the European Academy of Dermatology and Venereology annual congress in Prague, Czech Republic. [More]
Effective ways to reduce risk of vaginal yeast infection

Effective ways to reduce risk of vaginal yeast infection

Vaginal thrush is one of the most popular topics on NHS Choices website. This common yeast infection affects around 75% (three-quarters) of women at some point. Up to half of these will have thrush more than once. [More]
Long-term clinical follow up of children with primary vesicoureteric reflux

Long-term clinical follow up of children with primary vesicoureteric reflux

It is documented that vesicoureteric reflux (VUR) is a predisposing factor for UTI, which in turn may involve the kidney parenchyma and cause permanent renal scarring. [More]
Advertisement
Advertisement